In my previous role, I worked in the Pharma and was in the industry for about 20 years, but I felt that by working in medical affairs, I was also working closely with people. By with people, I mean people with diabetes first of all, and also with disease experts. So, in a role such as this, I would say that it involves working both for the company, with commercial interests, and for the real world, which is the world of patients and physicians. Being a bit in between, testing what disease experts and patients think about your solutions, and bringing that back internally to the company was really interesting for me.

A 62-year-old female was referred to her primary care physician for newly diagnosed Type 2 diabetes mellitus (T2DM). She was overweight…

Diabetes is one of the most significant comorbidities associated with COVID-19 susceptibility and severity,1 and recent statistics have…

Gastrointestinal (GI) symptoms represent an important and often poorly appreciated reason of morbidity in diabetes mellitus…

Patients with diabetes have a two-fold increase in the risk of heart failure (HF).

Diabetes and stroke, with an interlinking aetiology, contribute to a growing cardiovascular disease burden and mortality around the world…

Healthcare disparities and inequality are concepts that reflect aspects of differential healthcare access, disease and symptom management, and healthcare outcomes. Health inequalities can be defined as the “preventable, unfair and unjust differences in health status between groups, populations, or individuals that arise from the unequal distribution of social, environmental, and economic conditions within societies, which determine the risk of people getting ill, their ability to prevent sickness, or opportunities to take action and access treatment when ill health occurs.”1 Historically, disparities purely referred to a difference of some kind but, in recent years, the term has come to be synonymous with unfairness and inequality.

People with long-term conditions such as diabetes are at greater risk of comorbidity, and anecdotal evidence suggests that it can increase the burden of ongoing COVID-19 pandemic infection.1-3

Amivantamab has the potential to address the high unmet need in the treatment of people with EGFR exon 20 insertion mutations in non-small cell lung cancer

In this feature paper, the authors discuss the prevalence and pathophysiology of rheumatologic conditions, specifically ankylosing spondylitis and rheumatoid arthritis, in patients with hEDS.